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B cells play a crucial role in both humoral and adaptive immune 
responses and are detectable in murine and human atherosclerotic 
arteries. Recent findings from mouse models are starting to re-define 
the complex role(s) of B-cells in the atherosclerosis. We will discuss the 
involvement of different B-cell subsets in vascular pathology and how 
B cells could be targeted for therapeutic utility.
Atherosclerosis-related cardiovascular diseases are the leading 
cause of mortality worldwide. Multiple leukocyte subsets have been 
shown to play a significant role in atherosclerosis [1,2] and among 
them; B cells are receiving growing interest.
B cells play a crucial role in both humoral and adaptive immune 
responses. In addition to producing antibodies, B cells regulate T-cell 
responses via antigen presentation and cytokine production. Whilst it 
has been shown that patients with atherosclerosis produce antibodies 
against many antigens including oxidized low density lipoproteins 
(oxLDL), heat shock proteins (HSPs) and Chlamydia pneumoniae 
[3], the exact role of B cells in atherosclerosis has remained unclear, 
partly due to lack of knowledge on the existence of B cell subsets in 
humans. However, B cell subsets have been well characterized in mice, 
and both B1 and B2 cells have been shown to play important roles in 
atherosclerosis. B1 cells constitute a small percentage of B lymphocytes; 
they are derived from fetal or neonatal precursors and are usually found 
in the pleural and peritoneal cavities. B1 cells differentiate into B1a and 
B1b cells with respect to CD5 expression. Their main role is in innate 
immune responses, where they are responsible for the production of 
the majority of serum IgM [4,5]. B2 cells are the main population of B 
cells in spleen and lymph nodes and are the key producers of adaptive 
IgG antibody after they have been activated by specific antigens and 
have differentiated into plasma cells. B2 cells also function as antigen 
presenting cells and cytokine producers; they are therefore able to 
modulate T cell responses [4,5]. The concept of a third subpopulation of 
B cells with regulatory properties (Breg) was only recently introduced. 
A clear phenotypical characterization of Bregs is lacking, therefore all 
the B-cell subsets acting as immune regulators via IL-10 production 
are generally referred to as B10 cells [6]. Both natural and adaptive 
antibody responses are involved in atherosclerosis, as shown by the 
presence of IgM and IgG in atherosclerotic plaques [7,8].
B cells are found in atherosclerotic lesions in mice [9] and in 
humans [10]. In addition, B cells are present in the adventitia of normal 
and atherosclerotic arteries [11-13] and represent the major cells 
populating aortic tertiary lymphoid organs in aged apolipoprotein E 
deficient (apoE-/-) mice [14]. The role that B cells play in atherosclerosis 
has been the source of conflict in recent years, with studies by several 
groups pointing to an atheroprotective role for the cells, whilst others 
have demonstrated a pro-atherogenic function [15].
Key studies showing the protective role of B cells have been 
carried out by Caligiuri et al. [3] and Major et al. [16], using different 
mouse models of atherosclerosis. Caligiuri et al. [3] studied spleen 
associated immune activity in apoE-/- mice. The authors initially 
showed that splenectomy dramatically aggravated atherosclerosis in 
hypercholesterolemic apoE-/- mice and that the transfer of spleen cells 
from atherosclerotic apoE-/- mice significantly decreased development 
of atherosclerosis in young apoE-/- recipients. To identify which 
lymphocyte subset was immunoprotective, the group performed 
immunomagnetic separation before cell transfer to separate the T 
and B cells. They found that the B cells were conferring protection 
to atherosclerosis and were able to reduce disease in splenectomised 
apoE-/- mice. This protective effect was associated with an increase 
in antibody titers to oxLDL. Overall, these findings implied that B 
cells were playing a protective role in atherosclerosis [3]. Work by 
Major et al. [16] reached similar conclusions. The group used B-cell 
deficient (µMT) mice as bone marrow donors for irradiated low 
density lipoprotein receptor deficient (LDLR-/-) mice; recipients were 
subsequently shown to have <1% of their normal B cell population. 
The B cell deficient LDLR-/-) mice on a high fat diet had a marked 
decrease in their total serum antibody levels, and also in their antibody 
levels against ox-LDL. Furthermore, B cell deficiency was associated 
with a 30-40% increase in the lesion area [16]. These results again show 
a protective role for B cells in atherosclerosis.
Recently, the paradigm of protective B cells was challenged by Ait-
Oufella et al. [17] who examined lesion development in mice with or 
without B cell depletion via a CD20 monoclonal antibody, previously 
validated [18]. They began by studying apoE-/- mice fed a high fat 
western diet. The mice were treated with CD20 monoclonal antibody, 
which led to a sustained and profound decrease in the number of 
mature B cells in the blood, spleen, bone marrow and peritoneum. 
The group expected to see an exacerbation of atherosclerosis, however, 
they saw a significant reduction in lesion development. To rule out the 
possibility that this effect was due to the particular mouse model and 
diet, the group performed the same experiments on apoE-/- mice fed a 
chow diet, and also on LDLR-/- mice; again, they found that treatment 
with CD20 monoclonal antibody led to marked B cell depletion and 
to a significant decrease in atherosclerosis [17]. This B2 cell depletion 
was associated with decreased activated splenic CD4+ T cells, T-cell 
proliferation, and lesional T cell content. These results suggest a pro-
atherogenic role for B cells which had previously been unknown.
These discrepancies may relate to the subsets of B cells involved 
in atherosclerosis, particularly with regards to their role as antibody 
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producers. Numerous studies in humans have shown that the 
relationship between IgM anti-oxLDL levels and cardiovascular disease 
outcome are inversely correlated, whereas high IgG anti-oxLDL levels 
were positively associated with clinical cardiovascular events [19-21]. 
Furthermore, high levels of IgM anti- oxLDL are associated with a 
stable atherosclerotic plaque phenotype containing fewer macrophages 
and more extracellular matrix (ECM); high levels of IgG against oxLDL 
are related to an unstable plaque phenotype containing increased 
lipids and decreased ECM [22]. Overall, these data contribute to the 
hypothesis that IgM is playing a protective role in atherosclerosis whilst 
the IgG response is pro-atherogenic.
It is also possible that the methods used to study B cell depletion can 
impact on atherosclerotic outcome. Whilst splenectomy and the use of 
µMT-deficient mice investigated the role of depletion of B cells without 
regards to maturation state, use of the monoclonal CD20 antibody 
investigated the depletion of the mature B cell population [17]. Serum 
level of natural IgM antibody remained unchanged following B cell 
depletion, due the minimal depletion of peritoneal B1a cells. On the 
contrary, IgG antibodies against oxLDL were significantly decreased 
[17].
Interestingly, the direct contribution of different B-cell subsets 
to the pathology has been recently investigated. Kyaw et al. [23] 
showed that adoptive transfer of B2 cells (but not B1 cells) increased 
atherosclerosis in B-cell deficient (µMT) apoE-/- mice, confirming a 
pro- atherogenic role of this B2-cell subset [17,23]. The use of chimeric 
mice of mixed genotype (transfer of apoE+/+ C57BL/6 B cells into 
µMT apoE-/-) may confound interpretation of these data. However, 
Sage et al. [24] presented another important study confirming the 
impact of B2 cells on atherosclerosis by using a genetic strategy of B 
cell activating factor receptor (BAFFR) deficiency to deplete B2 cells. 
BAFFR is a tumor necrosis factor receptor family member that is 
critical for maintaining mature B2 B cells. The authors reconstituted 
lethally irradiated LDLr-/- mice with either wild type or BAFFR-
deficient bone marrow. BAFFR deficiency in bone marrow cells led to 
a marked reduction of conventional mature B2 cells but did not affect 
the B1a cell subtype. This was associated with a significant reduction 
of dendritic cell activation, T-cell proliferation, IgG antibodies against 
malondialdehyde- modified LDL along with a significant reduction 
in atherosclerotic lesion development. Consistent with these findings 
Kyaw et al. [25] recently demonstrated that depletion of B2 cells in 
BAFFR-deficient apoE-/- double KO mice reduced lesion formation 
and vascular inflamation Taken together, these studies clearly 
demonstrate a pro-atherogenic role for B2 cells. On the contrary 
B1a cells have been show to be atheroprotective [26]. Splenectomy 
of apoE-/- mice reduced peritoneal B1a cells, plasma IgM, oxLDL 
IgM and lesional IgM levels, which was accompanied by increased 
atherosclerotic lesion size, necrotic core, lesional oxLDL and apoptotic 
cells. These effects were reversed upon transfer of B1a cells. The authors 
showed that the protective effects of the B1a-cell subset were mediated 
by IgM secretion [26].
Yet several important questions remain unanswered. Are IL-10 
producing Bregs atheroprotective? What are the mechanisms whereby 
B-cell subsets influence atherosclerosis? Recently, an atheroprotective 
role for B cells homing the aorta has been described [13]. Which is net 
contribution of splenic vs arterial B cells to the pathology? And which 
B-cell subsets are predominant in healthy vs atherosclerotic vessels?
Answers to these questions would have important therapeutic 
implications. The therapies available today for preventing coronary artery 
disease and stroke rely almost exclusively on risk factor intervention, 
whereas therapies directly targeting vascular inflammation are lacking. 
B cell depletion appears as an effective therapy in many autoimmune 
diseases including rheumatoid arthritis (RA) however, research on 
cardiovascular effects of the chimeric antiCD20 monoclonal antibody 
(rituximab, RTX) has produced controversial results to date [27]. In a 
small clinical pilot study favorable effects are RTX on the lipidprofile, 
endothelial function and carotid intima/media thickness in RA patients 
have been reported [28]. However, the small number of patients 
analyzed in this study may confound interpretation. More recently, no 
significant change in arterial stiffness in RA patients after 6 months 
and 1 year of rituximab treatment was observed [29]. Unexpectedly, 
a reduced efficacy of RTX has been observed when administered with 
statins [30].
In conclusion, with regard to approaches aiming at B cell targeting 
it will be essential to develop B cell subset specific strategies that deplete 
B2 cells but do not affect B1a and regulatory B10 cells. Little is known 
about the effect of B cell targeting therapy in humans on different B 
cell subsets and therefore B cell therapy is still far away from clinical 
practice for atherosclerosis.
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